Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial

Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC

No benefit for adjuvant durvalumab in completely resected NSCLC

ESMO 2024: Highlights and analysis

Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy

Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours

ESMO 2024: Latest in EGFR mutated NSCLC

Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates improved clinical benefit in NSCLC

Assessment of suicide risk in cancer patients